Skip to main content

Case reports of heart failure after therapy with a tumor necrosis factor antagonist.

Publication ,  Journal Article
Kwon, HJ; Coté, TR; Cuffe, MS; Kramer, JM; Braun, MM
Published in: Ann Intern Med
May 20, 2003

BACKGROUND: Etanercept and infliximab are U.S. Food and Drug Administration-approved tumor necrosis factor (TNF) antagonists. OBJECTIVE: To describe adverse event reports of heart failure after TNF antagonist therapy. DESIGN: Case series. SETTING: The U.S. Food and Drug Administration's MedWatch program. PATIENTS: 47 patients who developed new or worsening heart failure during TNF antagonist therapy. MEASUREMENTS: Clinical and laboratory reports. RESULTS: After TNF antagonist therapy, 38 patients developed new-onset heart failure and 9 patients experienced heart failure exacerbation. Of the 38 patients with new-onset heart failure, 19 (50%) had no identifiable risk factors. Ten patients younger than 50 years of age developed new-onset heart failure after receiving TNF antagonists. After TNF antagonist therapy was discontinued and heart failure therapy was started in these 10 patients, 3 had complete resolution of heart failure, 6 improved, and 1 died. CONCLUSION: In a fraction of patients, TNF antagonists might induce new-onset heart failure or exacerbate existing disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

May 20, 2003

Volume

138

Issue

10

Start / End Page

807 / 811

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Tumor Necrosis Factor-alpha
  • Risk Factors
  • Receptors, Tumor Necrosis Factor
  • Middle Aged
  • Male
  • Infliximab
  • Immunoglobulin G
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kwon, H. J., Coté, T. R., Cuffe, M. S., Kramer, J. M., & Braun, M. M. (2003). Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med, 138(10), 807–811. https://doi.org/10.7326/0003-4819-138-10-200305200-00008
Kwon, Hyon J., Timothy R. Coté, Michael S. Cuffe, Judith M. Kramer, and M Miles Braun. “Case reports of heart failure after therapy with a tumor necrosis factor antagonist.Ann Intern Med 138, no. 10 (May 20, 2003): 807–11. https://doi.org/10.7326/0003-4819-138-10-200305200-00008.
Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003 May 20;138(10):807–11.
Kwon, Hyon J., et al. “Case reports of heart failure after therapy with a tumor necrosis factor antagonist.Ann Intern Med, vol. 138, no. 10, May 2003, pp. 807–11. Pubmed, doi:10.7326/0003-4819-138-10-200305200-00008.
Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003 May 20;138(10):807–811.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

May 20, 2003

Volume

138

Issue

10

Start / End Page

807 / 811

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Tumor Necrosis Factor-alpha
  • Risk Factors
  • Receptors, Tumor Necrosis Factor
  • Middle Aged
  • Male
  • Infliximab
  • Immunoglobulin G
  • Humans